8-K: Castle Biosciences Q1 2026 Earnings: Revenue Guidance Raised

Castle Biosciences reported first quarter 2026 results, with revenue of $83.7 million and an increase in total test reports for core drivers by 36%, leading to an upward revision of full-year revenue guidance.

Summary

• Castle Biosciences announced its first quarter 2026 financial results, reporting $83.7 million in revenue.
• Total test reports for core revenue drivers, DecisionDx-Melanoma and TissueCypher, increased by 36% compared to the first quarter of 2025.
• DecisionDx-Melanoma test reports grew 16% year-over-year, and TissueCypher test reports increased by 58% year-over-year.
• The company is raising its full-year 2026 revenue guidance to a range of $345 million to $355 million, up from the previous guidance of $340 million to $350 million.
• Net loss for the quarter was $14.5 million, or $0.49 per share, an improvement from a net loss of $25.8 million, or $0.90 per share, in the first quarter of 2025.
• Adjusted EBITDA was $(5.1) million, compared to $13.0 million in the prior year's first quarter.
• Cash, cash equivalents, and marketable investment securities totaled $261.7 million as of March 31, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with the company raising its revenue guidance and showing strong growth in key test volumes, despite a continued net loss and increased operating cash burn.

Positives

• Raised full-year 2026 revenue guidance to $345-355 million from $340-350 million.
• Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 36% year-over-year.
• DecisionDx-Melanoma test reports increased 16% year-over-year.
• TissueCypher test reports increased 58% year-over-year.
• Net loss improved to $14.5 million from $25.8 million in Q1 2025.
• Gross margin was 73% (GAAP) and Adjusted Gross Margin was 75.6% (Non-GAAP).
• Strong cash position of $261.7 million as of March 31, 2026.

Negatives

• Net cash used in operations was $22.1 million, compared to $6.0 million used in Q1 2025.
• Adjusted EBITDA was $(5.1) million, a decrease from $13.0 million in Q1 2025.
• GAAP revenue decreased to $83.7 million from $88.0 million in Q1 2025, impacted by changes in DecisionDx-SCC Medicare coverage and discontinuation of IDgenetix.
• DecisionDx-SCC test reports decreased to 3,702 from 4,375 in Q1 2025.

Risks

• The change in DecisionDx-SCC Medicare coverage effective April 24, 2025, affected first quarter 2026 revenue.
• The discontinuation of IDgenetix in May 2025 impacted revenue.
• The company faces risks related to reimbursement for its products and subsequent coverage decisions.
• Macroeconomic events and conditions, including inflation, labor shortages, and geopolitical events, could impact the business.
• Subsequent study or trial results may contradict earlier findings or not support the results discussed.
• The company may require additional financing in the future.

Future Outlook

Castle Biosciences is raising its full-year 2026 total revenue guidance to $345-355 million, up from the previous guidance of $340-350 million, reflecting confidence in the business's performance and continued growth of its core revenue drivers.

Management Comments

• The Castle Biosciences team delivered outstanding results to start 2026, delivering $83.7 million in revenue.
• Our momentum this quarter reflects our robust execution and the strength of our core revenue drivers, with both DecisionDx-Melanoma and TissueCypher achieving double digit year-over-year test volume growth, 16% and 58%, respectively.
• As a result of our first quarter performance and continued confidence in the business, we are raising our 2026 total revenue guidance to $345-355 million, compared to the previously provided guidance of $340-350 million.
• Our substantial body of evidence is a key driver of adoption and an important differentiator for DecisionDx-Melanoma and our innovative test portfolio more broadly, reinforcing our position of strength as we continue to execute across the business.

Industry Context

StockSavvy.ai notes that Castle Biosciences' performance in Q1 2026, particularly the growth in its core diagnostic tests like DecisionDx-Melanoma and TissueCypher, aligns with the broader trend in the healthcare industry towards personalized medicine and data-driven patient care. The company's focus on generating robust clinical evidence to support test adoption is a critical strategy in this competitive landscape.

Comparison to Industry Standards

• The 36% year-over-year increase in total test reports for core revenue drivers (DecisionDx-Melanoma and TissueCypher) demonstrates strong market penetration and adoption, potentially outpacing growth rates of some diagnostic peers.
• The company's Adjusted Gross Margin of 75.6% is a strong indicator of operational efficiency within the diagnostics sector, though direct comparisons require specific data from competitors like Guardant Health or Exact Sciences, which operate in different segments of the diagnostics market.
• The net loss of $14.5 million, while significant, shows improvement from the prior year, reflecting a common challenge for growth-stage diagnostic companies investing heavily in R&D and commercialization.

Stakeholder Impact

• Shareholders: Positive impact from raised revenue guidance and strong test volume growth, potentially leading to future value appreciation.
• Clinicians: Continued access to innovative diagnostic tests that guide patient care and improve outcomes.
• Patients: Benefit from more precise diagnosis and risk stratification, leading to personalized treatment plans and potentially improved health outcomes.

Next Steps

• Continue to execute on commercial strategies to drive test adoption.
• Expand the body of evidence supporting DecisionDx-Melanoma and other tests.
• Focus on R&D efforts to build evidentiary support and develop new tests.
• Monitor macroeconomic conditions and their potential impact on the business.

Key Dates

Recommendation

The company demonstrated positive operational momentum with raised guidance and strong test volume growth. However, the continued net loss, increased operating cash burn, and the impact of Medicare coverage changes on a specific product warrant a cautious 'hold' rating until further improvements in profitability and sustained revenue growth are evident.

Keywords

Castle Biosciences, Q1 2026 Earnings, DecisionDx-Melanoma, TissueCypher, Revenue Guidance, Medical Diagnostics, Oncology, Gastroenterology